<!DOCTYPE html>
<!--[if lt IE 7]>      <html class="no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]-->
<!--[if IE 7]>         <html class="no-js lt-ie9 lt-ie8"> <![endif]-->
<!--[if IE 8]>         <html class="no-js lt-ie9"> <![endif]-->
<!--[if IE ]> <html class="no-js IE"> <![endif]-->
<!--[if IE ]> <html class="no-js IE"> <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js"> <!--<![endif]-->
    <head>
        <meta charset="utf-8">
        <meta http-equiv="X-UA-Compatible" content="IE=edge">
        <title></title>
        <meta name="description" content="">
        <meta name="viewport" content="width=device-width, initial-scale=1">
        <link rel="stylesheet" href="css/styles.css">
        <link rel="stylesheet" href="css/customStyles.css">
    </head>
    <body class="newsPage">
        <div id="header">
            <div class="header agilvaxLogoSmallScreen center">
                <a href="index.html"><img src="images/agilvaxHeaderLogo.png" alt="Agilvax" title="Agilvax" width="135"></a>
            </div>

            <div class="navigation">
                    <div class="mobileNavToggle">Menu</div>
                    <div class="navigationBar">
                        <ul class="nav navLeft">
                        </ul><!-- /nav -->
                        <ul class="nav navRight">
                        </ul><!-- /nav -->
                    </div><!-- /navigationBar -->
            </div><!-- /navigation -->
        </div><!-- #header -->

        <div class="pageTitle">
            <div class="containerNarrow">
                <h1 class="slideInBT">Agilvax News</h1>
            </div>
        </div><!-- /pageTitle -->
        <div class="mainContent">
            <div class="containerNarrow">
                <div class="greenCard AgilvaxSolution newsletterForm">
                    <p><b>Subscribe to our newsletter to stay informed about important Agilvax news.</b></p>
                    <form action="http://agilvaxinc.createsend.com/t/t/s/kjtjlu/" method="post" id="subForm">
                        <div class="twoFifths breakColMobile">
                            <p>
                                <label for="fieldName">Name</label><br />
                                <input id="fieldName" name="cm-name" type="text" />
                            </p>
                        </div><!-- /twoFifths breakColMobile -->
                        <div class="twoFifths breakColMobile">
                            <p>
                                <label for="fieldEmail">Email</label><br />
                                <input id="fieldEmail" name="cm-kjtjlu-kjtjlu" type="email" required />
                            </p>
                        </div><!-- /twoFifths breakColMobile -->
                        <div class="oneFifth breakColMobile gridLast">
                            <p>
                                <br><button type="submit" class="btn primaryBtn">Subscribe</button>
                            </p>
                        </div><!-- /oneFifth breakColMobile gridLast -->
                    </form>
                </div><!-- /newsletterForm -->

                <div class="newsArticle">
                    <a href="Faith-Charles-Joins-Agilvax-Board-Of-Directors.html" class="pictureFrame"><img src="images/news/agilvax.gif" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="Faith-Charles-Joins-Agilvax-Board-Of-Directors.html">Faith Charles Joins Agilvax’s Board Of Directors</a></h2>
                        <p class="author">Albuquerque, NM</p>
                        <p class="date">September 14, 2016</p>
                        <p>Agilvax, Inc. today announced that Faith L. Charles, partner in Thompson Hine‘s Corporate Transactions & Securities practice group and chair of the firm’s Life Sciences group, has been elected to Agilvax’s board of directors, effective September 13, 2016.</p>
                        <p><a href="Faith-Charles-Joins-Agilvax-Board-Of-Directors.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div>

                <div class="newsArticle">
                    <a href="n-Agilvax-Receives-New-Patent-for-its-Cost-Effective-Broadly-Protective-HPV-Vaccine-Candidate.html" class="pictureFrame"><img src="images/news/agilvax.gif" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="n-Agilvax-Receives-New-Patent-for-its-Cost-Effective-Broadly-Protective-HPV-Vaccine-Candidate.html">Agilvax Receives New Patent for Its Cost-Effective Broadly Protective HPV Vaccine Candidate</a></h2>
                        <p class="author">Albuquerque, NM</p>
                        <p class="date">September 06th, 2016</p>
                        <p>Agilvax, Inc. a leader in the discovery and development of vaccines and cancer immunotherapies is pleased to announce the Notice of Allowance by the U.S. Patent and Trademark office on August 26, 2016 of a new patent related to the company’s human papillomavirus (HPV) vaccine candidate.</p>
                        <p><a href="n-Agilvax-Receives-New-Patent-for-its-Cost-Effective-Broadly-Protective-HPV-Vaccine-Candidate.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div>

                <div class="newsArticle">
                    <a href="n-Agilvax-Appoints-Dr-Brad-Vale.html" class="pictureFrame"><img src="images/news/agilvax.gif" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="n-Agilvax-Appoints-Dr-Brad-Vale.html">Agilvax Appoints Dr. Brad Vale Former Head of Johnson & Johnson Development Corporation (JJDC) to its Board Of Directors</a></h2>
                        <p class="author">Albuquerque, NM</p>
                        <p class="date">July 20th, 2016</p>
                        <p>Agilvax, Inc. today announced it has appointed Brad Vale, PhD, DVM to its Board of Directors.  Dr. Vale is an expert corporate executive in the biotechnology, pharmaceutical and medical device investing arena. His appointment was effective July 20th 2016.</p>
                        <p><a href="n-Agilvax-Appoints-Dr-Brad-Vale.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div>

                <div class="newsArticle">
                    <a href="n-SBIR-Grant.html" class="pictureFrame"><img src="images/news/agilvax.gif" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="n-SBIR-Grant.html">Agilvax Receives SBIR Grant to Advance Development of A VLP Based RSV Vaccine</a></h2>
                        <p class="author">Albuquerque, NM</p>
                        <p class="date">July 6th, 2016</p>
                        <p>National Institute of Allergy and Infectious Diseases (NIAID) has awarded Agilvax a one-year, $286,000 grant under the Small Business Innovation Research (SBIR) program entitled “Development of a VLP-based RSV vaccine targeting pre-fusion F protein.”</p>
                        <p><a href="n-SBIR-Grant.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div><!-- /newsArticle -->

                <div class="newsArticle">
                    <a href="n-Notice-of-Allowance-for-US-and-European-Patents.html" class="pictureFrame"><img src="images/news/agilvax.gif" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="n-Notice-of-Allowance-for-US-and-European-Patents.html">Agilvax Receives Notice of Allowance for U.S. and European Patents Covering its Vaccine and Cancer Immunotherapy Discovery and Development Platform Technology</a></h2>
                        <p class="author">Albuquerque, NM</p>
                        <p class="date">February 29th, 2016</p>
                        <p>Agilvax, Inc. is pleased to announce that it has recently received a Notice of Allowance in United States Patent Application serial number 13/520,057 and an Intention to Grant in European Patent Application 10841780.9 entitled, “Plasmids and Methods for Peptide Display and Affinity-Selection on Virus-Like Particles of RNA Bacteriophages”.</p>
                        <p><a href="n-Notice-of-Allowance-for-US-and-European-Patents.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div><!-- /newsArticle -->

                <div class="newsArticle">
                    <a href="nAgilvax-to-Attend-The-34th-Annual-J.P.-Morgan-Healthcare-Conference-and-the-8th-Annual-Biotech-Showcase-Conference.html" class="pictureFrame"><img src="images/news/agilvax.gif" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="nAgilvax-to-Attend-The-34th-Annual-J.P.-Morgan-Healthcare-Conference-and-the-8th-Annual-Biotech-Showcase-Conference.html">Agilvax to Attend The 34th Annual J.P. Morgan Healthcare Conference and the 8th Annual Biotech Showcase Conference</a></h2>
                        <p class="author">Albuquerque, NM</p>
                        <p class="date">January 8, 2016</p>
                        <p>Agilvax Inc., announced today that Dr. Federica Pericle, President & CEO, and Michael Perrine, Director of Business Development will be representing Agilvax during the 34th Annual J.P. Morgan Healthcare Conference and the 8th Annual Biotech Showcase Conference in San Francisco, CA January 11-14, 2016.</p>
                        <p><a href="nAgilvax-to-Attend-The-34th-Annual-J.P.-Morgan-Healthcare-Conference-and-the-8th-Annual-Biotech-Showcase-Conference.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div><!-- /newsArticle -->


                <div class="newsArticle">
                    <a href="nAgilvax-IBT.html" class="pictureFrame"><img src="images/news/Agilvax-IBT.gif" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="nAgilvax-IBT.html">Agilvax announces Strategic Collaboration with Integrated BioTherapeutics to Develop a Novel Pan-Ebola Vaccine</a></h2>
                        <p class="author">Albuquerque, NM</p>
                        <p class="date">July 20, 2015</p>
                        <p>Agilvax, Inc. today announced a collaboration with Integrated BioTherapeutics (IBT), a leader in filovirus and other emerging infectious disease research, to develop novel vaccines against filoviruses such as Ebola and Marburg.</p>
                        <p><a href="nAgilvax-IBT.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div><!-- /newsArticle -->

                <div class="newsArticle">
                    <a href="nNMSBA.html" class="pictureFrame"><img src="images/news/agilvax.gif" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="nNMSBA.html">Agilvax to Collaborate With Sandia National Laboratories & NMSBA To Develop Vaccines And Immunotherapies That Lack Cold-chain Requirements</a></h2>
                        <p class="author">Albuquerque, NM</p>
                        <p class="date">May 12, 2015</p>
                        <p>Agilvax, Inc. announced an agreement with Sandia National Laboratories to optimize the long-term stability and efficacy of the Company’s products.</p>
                        <p><a href="nNMSBA.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div><!-- /newsArticle -->

                <div class="newsArticle">
                    <a href="n-Agilvax-Present-At-ChinaBio-Partnering-Forum-2015.html" class="pictureFrame"><img src="images/news/agilvaxChinaBio.png" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="n-Agilvax-Present-At-ChinaBio-Partnering-Forum-2015.html">Agilvax To Present At The 2015 Annual Conference On Vaccine Research and Attend The 7th Annual ChinaBio Partnering Forum</a></h2>
                        <p class="author">Albuquerque, NM</p>
                        <p class="date">April 8, 2015</p>
                        <p>Agilvax Inc., a biotechnology company that develops vaccines and immunotherapies to combat infectious diseases and cancer, announced today that Dr. Mitchell Tyler, Director of Research & Development, will be presenting a poster at the 2015 Annual Conference on Vaccine Research in Bethesda, MD April 13-15, 2015.</p>
                        <p><a href="n-Agilvax-Present-At-ChinaBio-Partnering-Forum-2015.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div><!-- /newsArticle -->

                <div class="newsArticle">
                    <a href="nAgilvaxToAttendBioAsiaIntl.html" class="pictureFrame"><img src="images/news/agilvax.gif" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="nAgilvaxToAttendBioAsiaIntl.html">Agilvax to Attend 12th Annual Bio Asia International Conference</a></h2>
                        <p class="author">Albuquerque, NM</p>
                        <p class="date">March 18, 2015</p>
                        <p>Agilvax Inc., a biotechnology company that develops vaccines and immunotherapies to combat infectious diseases and cancer, announced today that that President & CEO, Federica Pericle, will attend the 12th Annual Bio Asia International Conference in Tokyo, Japan, March 24-25, 2015.</p>
                        <p><a href="nAgilvaxToAttendBioAsiaIntl.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div><!-- /newsArticle -->


                <div class="newsArticle">
                    <a href="nHumabs-Press-Release.html" class="pictureFrame"><img src="images/news/agilvax-humbas.png" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="nHumabs-Press-Release.html">Agilvax Announces Strategic Collaboration with Humabs BioMed SA to Develop Targeted Vaccines and Immunotherapies</a></h2>
                        <p class="author">Albuquerque, NM</p>
                        <p class="date">February 17, 2015</p>
                        <p>Agilvax, Inc. today announced a collaboration with Switzerland based Humabs BioMed that will contribute to the rapid advancement of Agilvax’s ever expanding vaccine and immunotherapy pipeline.</p>
                        <p><a href="nHumabs-Press-Release.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div><!-- /newsArticle -->
                <div class="newsArticle">
                    <a href="nAdvancingClinicalProductionOfItsLeadVaccineAgainstHumanPapillomaVirus.html" class="pictureFrame"><img src="images/news/agilvax.gif" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="nAdvancingClinicalProductionOfItsLeadVaccineAgainstHumanPapillomaVirus.html">Agilvax Is Advancing Clinical Production of its Lead Vaccine Against Human Papillomavirus (HPV)</a></h2>
                        <p class="author">Albuquerque, NM</p>
                        <p class="date">February 03, 2015</p>
                        <p>Albuquerque, NM (February 03, 2015) - Agilvax, Inc. announced an agreement with the Division of Microbiology and Infectious Diseases (DMID) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) to expedite the clinical development of Agilvax’s virus-like-particle (VLP) vaccine targeting human papillomavirus (HPV).</p>
                        <p><a href="nAdvancingClinicalProductionOfItsLeadVaccineAgainstHumanPapillomaVirus.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div><!-- /newsArticle -->
                <div class="newsArticle">
                    <a href="nAgilvaxToAttendBiotechShowcase2015.html" class="pictureFrame"><img src="images/news/BiotechShowcase2015.jpg" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="nAgilvaxToAttendBiotechShowcase2015.html">Agilvax To Attend Biotech Showcase™ 2015</a></h2>
                        <p class="author">Albuquerque, NM</p>
                        <p class="date">January 5, 2015 </p>
                        <p>Agilvax Inc. announced today that Michael Perrine, MS, MBA, Director of Business Development will be representing the company at the 7th Annual Biotech Showcase™ in San Francisco January 12-14, 2015.  Agilvax welcomes the opportunity to discuss its first-in-class immunotherapy and vaccine discovery and development platform.</p>
                        <p><a href="nAgilvaxToAttendBiotechShowcase2015.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div><!-- /newsArticle -->
                <div class="newsArticle">
                    <a href="nRMVCA2014ABQPitchUnplugged.html" class="pictureFrame"><img src="images/news/rockyMountainVentureCapitalAssociation.jpg" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="nRMVCA2014ABQPitchUnplugged.html">Agilvax President and CEO, Federica Pericle, tied for first place at the RMVCA2014: ABQ Pitch Unplugged</a></h2>
                        <p class="author">Albuquerque, NM</p>
                        <p class="date">August 28, 2014</p>
                        <p>On Thursday August 28, 2014 Agilvax President and CEO, Federica Pericle, tied for first place at the Rocky Mountain Venture Capital Association 2014 ABQ Pitch Unplugged event at Albuquerque’s Marble Brewery.</p>
                        <p><a href="nRMVCA2014ABQPitchUnplugged.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div><!-- /newsArticle -->
                <div class="newsArticle">
                    <a href="nAgilvaxLands2MillionInSeriesAFunding.html" class="pictureFrame"><img src="images/news/agilvaxLands2M.jpg" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="nAgilvaxLands2MillionInSeriesAFunding.html">Agilvax Lands $2 Million In Series A Funding</a></h2>
                        <p class="author">By Dan Mayfield / Reporter-Albuquerque Business First</p>
                        <p class="date">July 31, 2014</p>
                        <p>Albuquerque biotech firm Agilvax has landed $2 million in Series A funding to develop its virus-like particle technology. </p>
                        <p><a href="nAgilvaxLands2MillionInSeriesAFunding.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div><!-- /newsArticle -->
                <div class="newsArticle">
                    <a href="nUNMTechSpeedingUpVaccineDev.html" class="pictureFrame"><img src="images/news/UNMTechSpeedingUpVaccineDev.jpg" width="190"></a>
                    <div class="excerpt">
                        <h2><a href="nUNMTechSpeedingUpVaccineDev.html">UNM Tech Speeding Up Vaccine Development</a></h2>
                        <p class="author">By Kevin Robinson-Avila / Journal Staff Writer</p>
                        <p class="date">June 23, 2014</p>
                        <p>An Albuquerque startup may soon bring the world’s first vaccines for malaria and dengue to market with break through technology from the University of New Mexico.</p>
                        <p><a href="nUNMTechSpeedingUpVaccineDev.html" class="btn primaryBtn readMoreLink">Read More</a></p>
                    </div><!-- /excerpt -->
                </div><!-- /newsArticle -->
            </div><!-- /containerNarrow -->
        </div><!-- /MainContent -->
       


        <div id="footer">
        </div><!-- /footer -->

        <script src="http://ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>
        <script src="http://ajax.googleapis.com/ajax/libs/jqueryui/1.10.4/jquery-ui.min.js"></script>
        <script src="js/modernizr-2.6.2.min.js"></script>
        <script src="js/plugins.js"></script>

        <!-- LoadIncludes -->
        <script>
            $( ".navLeft" ).load( "includes/nav.html" );
            $( ".navRight" ).load( "includes/navRight.html" );
            $( "#footer" ).load( "includes/footer.html" );
        </script>
        <script src="js/main.js"></script>

    </body>
</html>